Plasma proteomic characterization of colorectal cancer patients with FOLFOX chemotherapy by integrated proteomics technology
Authors (first, second and last of 7)
Collection
Clinical translation of targeted proteomics
Accurate and rapid performance of medical diagnostic tests is a critical requirement for molecular diagnosis and disease treatment. While immunoassays are used in the majority of in vitro diagnostics, limitations such as cross-reactivity, low sensitivity, and limited dynamic range, compel clinical laboratories to seek better solutions that are highly sensitive, reproducible and specific, while also providing high throughput.
Recent advancements in new analytical methods and techniques over the last decade, specifically mass spectrometry (MS)-based targeted proteomic analytical methods and techniques, now allow for the highly reproducible and precise measurement of nearly every human protein. Nevertheless, translating these methods and techniques into ‘clinical grade’ assays presents many challenges.
We invite submissions for this special issue that focuses on the clinical translation of targeted MS proteomics and associated technologies.
Articles (14 in this collection)
-
-
Simultaneous targeted and discovery-driven clinical proteotyping using hybrid-PRM/DIA
Authors (first, second and last of 11)
-
Quantitative proteomic analysis of HER2 protein expression in PDAC tumors
Authors (first, second and last of 16)
-
Closing the gaps in patient management of dyslipidemia: stepping into cardiovascular precision diagnostics with apolipoprotein profiling
Authors (first, second and last of 4)
-
Highly sensitive therapeutic drug monitoring of infliximab in serum by targeted mass spectrometry in comparison to ELISA data
Authors (first, second and last of 9)
-
Lessons learned: establishing a CLIA-equivalent laboratory for targeted mass spectrometry assays – navigating the transition from research to clinical practice
Authors (first, second and last of 16)
-
Absolute quantitation of human wild-type DNAI1 protein in lung tissue using a nanoLC-PRM-MS-based targeted proteomics approach coupled with immunoprecipitation
Authors (first, second and last of 9)
-
Recent developments in mass-spectrometry-based targeted proteomics of clinical cancer biomarkers
Authors (first, second and last of 4)
-
An LC–MS-based designated comparison method with similar performance to the Lp(a) reference measurement procedure to guide molar Lp(a) standardization
Authors (first, second and last of 6)
-
Quantification of putative ovarian cancer serum protein biomarkers using a multiplexed targeted mass spectrometry assay
Authors (first, second and last of 6)
-
Mass spectrometry quantifies target engagement for a KRASG12C inhibitor in FFPE tumor tissue
Authors (first, second and last of 8)
-
Change of histone H3 lysine 14 acetylation stoichiometry in human monocyte derived macrophages as determined by MS-based absolute targeted quantitative proteomic approach: HIV infection and methamphetamine exposure
Authors (first, second and last of 7)
-
Glial cell proteome using targeted quantitative methods for potential multi-diagnostic biomarkers
Authors (first, second and last of 11)
-
A large-scale targeted proteomics of serum and tissue shows the utility of classifying high grade and low grade meningioma tumors
Authors (first, second and last of 15)
